A Phase Ib/II Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung Cancer
NCT ID: NCT01784107
Last Updated: 2016-02-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
45 participants
INTERVENTIONAL
2011-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Phase 2 : To analyse efficacy and toxicity of Belotecan and Ifosfamide.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung Cancer
NCT03613753
A Clinical Study of Liposomal Doxorubicin Combined With Ifosfamide Second-line Treatment in Small Cell Lung Cancer
NCT01872416
Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients
NCT01783834
Second-line Treatment in Patients With Small Cell Lung Cancer (SCLC)
NCT00418743
Topotecan for Irinotecan-Refractory SCLC
NCT00502762
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Belotecan and Ifosfamide
Belotecan and Ifosfamide
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Belotecan and Ifosfamide
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* no prior chemotherapy or radiotherapy for lung
* measurable lesion for RECIST
* over 18 years
* ECOG 0\~2
* expected life span more than 3 months
Exclusion Criteria
* uncontrolled cerebral nerve symptoms or metastasis
* significant myocardial infarction or cardiac disease within 12 months
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gachon University Gil Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Eun Kyung Cho
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gachon University Gil Medical Center
Incheon, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-GIRBA-2550
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.